1. Blackwelder WC. „Proving the null hypothesis“ in clinical trials. Controlled Clinical Trials 1982; 3: 345–353.
2. EMEA/CPMP. Concept Paper on the development of a Committee for Proprietary Medicinal Products (CPMP) Points to Consider on biostatistical/methodological issues arising from recent CPMP discussions on licensing applications: Choice of Delta. London, UK: Committee for Proprietary Medicinal Products. 1999. CPMP/EWP/2158/99 (
http://www.emea.eu.int
/pdfs/human/ewp/215899en.pdf).
3. EMEA/ CPMP. Points to Consider on switching between superiority and non-inferiority. London, UK: Committee for Proprietary Medicinal Products. Approved by the
http://www.emea.eu.int
CPMP July 2000. CPMP/EWP/482/99 (/pdfs/human/ewp/048299en).
4. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Statistics in Medicine 1990; 9: 1447–1454.
5. Harrer G, Hübner WD, Podzuweit H. Wirksamkeit und Verträglichkeit des Hypericum- Präparates LI160 im Vergleich mit Maprotilin. Nervenheilkunde 1993; 12: 297–301.